Floatz logo

DYNAMOS

Fatty Liver Disease

Yale UniversitySmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

26 Active assets in the Fatty Liver Disease cohort.

Asset / SponsorPhaseRating
Metformin
Leiden University Medical Center
Phase 4BBB
Alpha Tocopherol
Yuen Kah Hay
Phase 4BB
Raltegravir
Helsinki University Central Hospital
Phase 4BB
Rilpivirine
Fundacion SEIMC-GESIDA
Phase 4BB
Empagliflozin
Seoul National University Bundang Hospital
Phase 4BB

View all 50 →

Same molecule, other indications

DYNAMOS is also rated in:

malignant pancreatic neoplasmDormant
B
Indicative ·
62 / 100
View asset →
metabolic dysfunction-associated steatohepatitisDormant
B
Indicative ·
60 / 100
View asset →
MASH - Metabolic Dysfunction-Associated SteatohepatitisDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →